Zilucoplan not checked

UCB Biopharma SRL · RA101495

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2/3 trial completes
Trials
3 active
7 in total · 5 in the EU
Targets
 

What this is

How it works
Blocks part of the complement system, a branch of the immune system that can attack the body's own cells.Complement Inhibitor FDA class
How it’s given
“Zilucoplan will be administered subcutaneously to pediatric study participants”In the company’s words, NCT06435312 on ClinicalTrials.gov
Tested for
Generalized Myasthenia Gravis (2 trials)
Main trialPhase 3
“The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants”In the company’s words, NCT06435312 on ClinicalTrials.gov
Other names
RA101495

Other drugs for Generalized Myasthenia Gravis

All 37 drugs for Generalized Myasthenia Gravis

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Enrolling by invitation 26 Oct 2027 An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Phase 2/3Recruiting 12 May 2027 A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Phase 1Recruiting 23 Mar 2027 A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Phase 3Completed 13 Mar 2024 An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Phase 3Completed 28 Jan 2025 A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
Phase 3Completed 31 Jul 2026 Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Phase 1Completed 26 Nov 2024 A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Zilucoplan

Following is part of Solo: you see every change to Zilucoplan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in